✦ LIBER ✦

Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK

✍ Scribed by K.T. Papazisis; T. Habeshaw; D.W. Miles

Book ID: 110880285
Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 139 KB
Volume: 58
Category: Article
ISSN: 1368-5031
DOI: 10.1111/j.1368-5031.2004.00203.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of HER2-positive metastatic br

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience

✍ Sutherland, S; Ashley, S; Miles, D; Chan, S; Wardley, A; Davidson, N; Bhatti, R; 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 450 KB

Determination of HER2 Gene Amplification

Determination of HER2 Gene Amplification by FluorescenceIn situHybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab

✍ Noël Dybdal; Grazyna Leiberman; Steven Anderson; Bryan McCune; Alex Bajamonde; R 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 237 KB

Anastrozole alone or in combination with

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer : Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses

✍ The ATAC (Arimidex; Tamoxifen Alone or in Combination) Trialists' Group 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 2 views

## Abstract ## BACKGROUND The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow‐up, 33 months) demonstrated that in adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer, anastrozole was superior to tamoxifen in terms of d